TNFRSF8 and plasma cell myeloma: These include Dasatinib (EPHA2), Moxetumomab pasudotox (CD22) and Inotuzumab ozogamicin (CD22) indicated in the treatment of leukaemia subtypes, Brentuximab vedotin (TNFRSF8), Polatuzumab vedotin (CD79B) and Pembrolizumab (PDCD1) indicated in the treatment of NHL subtypes including DLBCL, Elotuzumab (SLAMF7) indicated in the treatment of multiple myeloma, and Regorafenib (EPHA2, PDGFRA, FGFR2) indicated in the treatment of liver cancers (Supplementary Data 5).